Stock Ratings / Health Care / CPHI / options

ABVC (34) CELU (34) BCTX (41) RNAZ (47) ⌘ Pro Terminal →

China Pharma Holdings Inc. (CPHI) Options Positioning, Max Pain & Unusual Sweeps

$0.65 +4.84% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.65

China Pharma Holdings Inc. (CPHI) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $28.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.65 (+0.68%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 2.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CPHI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY CPHI SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (24% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 40.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$0.87-18.4% Next Q

Q2 (-2Q)

Grade C-$0.71-7% Next Q

Q3 (-1Q)

Grade D$0.66-1.5% Next Q

Current

Grade D$0.65-6.3% Hist 90D α

Trajectory: C- (53) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CPHI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CPHI currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.76) and Max Pain ($0.68) forces dealer call-delta covering toward $20.15.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CPHI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CPHI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CPHI)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CPHI.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CPHI)

✓Walkthrough of CPHI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CPHI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.37%⚡ TESTING RESISTANCE

2026-10-30O $0.65H $0.67L $0.61C $0.65VOL 182.5K

RES: $1.25SUP: $0.60SMA50: $0.76SMA200: $0.83

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CPHI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CPHI Butterfly Map → + Track CPHI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -8.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CPHI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CPHI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CPHI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CPHI)

Health Care Rank #489 of 1016 ⚔️ ABVC vs CPHI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CPHI vs. ABVC, CELU, BCTX, RNAZ)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, China Pharma Holdings Inc. (CPHI) ranks #489 by composite RQD confidence (45/100, grade D) and #810 by equity capitalization ($28.0M). Within this direct 5-issuer industry benchmark cohort, CPHI leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. RNAZ currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with CPHI at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CPHI ACTIVE China Pharma Holdings Inc.	D	45/100	—	-3.2%	-11.4%	+4.84%	$28.0M	Benchmark Subject
ABVC ABVC BioPharma Inc.	E	34/100	—	—	-35.0%	-4.59%	$27.8M	/abvc-vs-cphi →
CELU Celularity Inc. (Class A)	E	34/100	—	24.4%	-35.0%	-9.66%	$27.6M	/celu-vs-cphi →
BCTX BriaCell Therapeutics Corp.	D-	41/100	—	—	—	-5.43%	$28.9M	/bctx-vs-cphi →
RNAZ TransCode Therapeutics Inc.	D	47/100	—	—	-35.0%	-0.57%	$29.3M	/rnaz-vs-cphi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001106644

In its most recent audited fiscal period (FY2025, filed 2025-12-31), China Pharma Holdings Inc. (CPHI) reported GAAP revenue of $4.1M (-8.5% vs. FY2024 revenue of $4.5M , and -40.9% cumulative change since FY2023) , GAAP net income of -$3.2M, operating cash flow of $148.3K, and free cash flow of $88.9K (+120.0% YoY). On the balance sheet, CPHI closed FY2025 with $31.0M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.1M	-$3.2M	$148.3K	$88.9K	$31.0M	—
FY2024 (FY)	2024-12-31	$4.5M	-$4.7M	-$406.1K	-$444.5K	$14.9M	—
FY2023 (FY)	2023-12-31	$7.0M	-$3.1M	-$699.7K	-$699.7K	—	—

3. CPHI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CPHI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, China Pharma Holdings Inc. (NYSE: CPHI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.65 (+4.84% 1D, market cap $28.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CPHI ranks #489 in composite RQD confidence.

How does CPHI compare to ABVC and CELU in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CPHI carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of -3.2%, and ROIC of -11.4%. By comparison, ABVC (ABVC BioPharma Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $27.8M) and CELU (Celularity Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $27.6M). Among the 5-stock peer group, CPHI leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CPHI?

Per CPHI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001106644), China Pharma Holdings Inc. generated $4.1M in revenue (-8.5% YoY), -$3.2M in net income, and $88.9K in free cash flow against $31.0M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CPHI trading relative to its 50-day, 200-day, and 52-week technical levels?

CPHI last traded at $0.65 (+4.84% on volume of 154,589 shares), positioning the stock -14.47% below its 50-day simple moving average ($0.76) and -21.69% below its 200-day simple moving average ($0.83). Across its 52-week range of $0.38 to $19.19, CPHI sits at the 1.4% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.73).

CPHI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CPHI's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CPHI.

Direct Sub-Reports: CPHI RQD Cockpit CPHI 12M Forecast CPHI Earnings & Move CPHI Dividends & DRIP CPHI Insiders & 13F CPHI Whale Options CPHI Profit Sankey CPHI News & Why